NYSE:GI

EndoChoice (GI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$8.00
$8.00
50-Day Range
N/A
52-Week Range
$3.64
$9.47
Volume
N/A
Average Volume
131,115 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GI stock logo

About EndoChoice Stock (NYSE:GI)

EndoChoice Holdings, Inc. is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems. The Company's products are used in colonoscopy and procedures of the upper GI tract, including esophagogastroduodenoscopy (EGD). The Company's imaging products include Fuse system, EndoCart, and Endoscope repair and maintenance. The Company's single-use therapeutic devices include Neptune injection needle, Boa polypectomy snare, Rescue retrieval devices, Blox bite block, TrapEase polyp traps, Hydra irrigation system, EndoGlide+, Compliance EndoKit, SafeStart, EndoKit, CinchPad and GI pathology. The Company serves over 2,500 GI departments that perform endoscopic procedures.

GI Stock News Headlines

BUY ALERT: Tiny tech play partners with US government
The Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).
BUY ALERT: Tiny tech play partners with US government
The Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).
Best Hospitals for Gastroenterology & GI Surgery
EndoChoice Holdings, Inc.(GI)
See More Headlines
Receive GI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EndoChoice and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/04/2016
Today
5/04/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

GI Stock Analysis - Frequently Asked Questions

How were EndoChoice's earnings last quarter?

EndoChoice Holdings Inc (NYSE:GI) released its quarterly earnings data on Wednesday, May, 4th. The medical equipment provider reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.13. The medical equipment provider had revenue of $18.46 million for the quarter, compared to the consensus estimate of $18.34 million. EndoChoice's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.00) earnings per share.

What other stocks do shareholders of EndoChoice own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EndoChoice investors own include Cognyte Software (CGNT), Coeur Mining (CDE), Calithera Biosciences (CALA), DarioHealth (DRIO), Foresight Energy (FELP), (FMSA) (FMSA), Gran Tierra Energy (GTE), NewAge (NBEV), Nam Tai Property (NTP) and On Track Innovations (OTIV).

When did EndoChoice IPO?

EndoChoice (GI) raised $101 million in an initial public offering (IPO) on Friday, June 5th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, BofA Merrill Lynch, William Blair and Stifel acted as the underwriters for the IPO.

This page (NYSE:GI) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners